Hints and tips:
...Russia will have produced 2m doses of its Sputnik vaccine within the next few days, according to Mr Putin....
...The companies together own Kevzara, a rheumatoid arthritis drug, and Dupixent, an eczema medication. The sale is “a big opportunity to redeploy capital to do good science”, Mr Hudson said....
...The usual price discount enjoyed by value stocks was also unusually small at the end of the financial crisis, setting them up for a poorer performance, according to Mr Inker....
...During such interview, Mr....
...In that time AstraZeneca’s gone up 187 per cent and is the FTSE 100’s biggest company. Mr Soriot hasn’t been shy in the past about suggesting he’s underpaid, though shareholders tend to disagree....
...The US pharma sector already trades at a discount to the S&P 500, according to JPMorgan....
...LA’s jewellery district, began in earnest in 1978, when New York investors bought a nine-storey office building at 607 S....
...The company has warned that this structure could hit its valuation because it will not be included in key stock market indices tracked by investors such as the S&P 500, Russell 200 and S&P MidCap 400....
...The Russell, in turn, has gained nearly 6 per cent versus the 1.4 per cent gain for the S&P 500....
...Indeed, Mr Piotroski plumped for the old classic value measure of price-to-book (P/BV)....
...The S&P 500, Dow Jones Industrial Average, the Nasdaq Composite and Russell 2000 all notched new all-time highs on Friday. The Dow, up 0.72 per cent at 19,756.85, is close to the 20,000 milestone....
...Valuations are currently in line with the S&P 500, compared with the 1990s commodities downturn, when they traded at a 20 per cent discount to the S&P 500....
...In contrast, Next and M&S are on course for margins of 20 per cent and 6.5 per cent, according to estimates from S&P CIQ....
...S&P 500....
...Mr Blatter will be addressing attendees in his role as Fifa president. (Reuters) Marking the Fall of Saigon Vietnam today marks the end of the Vietnam war....
...Mr Ablin points to metrics including the price-to-sales ratio, which stands at 1.84 times 2015 results for the S&P 500 healthcare sector, in line with the blue-chip index and below that of the technology...
...Mr Mehta lowered his rating on Peabody to ‘sell’ from ‘neutral’, sending its shares 5 per cent lower to $13.49....
...Mr Roden added large biotech groups, flush with cash from recent drug hits, would aid shares of smaller companies in the sector....
...Mr Rolet may see in Russell the North American foothold TMX investors denied him. As an alumnus he will be aware nothing is more conducive to overpayment than an auction organised by Goldman Sachs....
...The Russell Growth 1000 is under particularly close surveillance, as the index, which favours high-growth companies, had outperformed the S&P 500 by 4.3 per cent over the past year at its peak in early March...
...Mr French was naturally proud of the upcoming VNDSL dividend and the achievement it represented — it took two years and 165 comments from the SEC before the S-1 offering document was approved....
...The S&P 500 is on course to gain 5 points to 1,844, just 4 points off its record close, and this move is feeding broader investor optimism....
...Applying a 30 times forward multiple, and then discounting back five years at a 15 per cent discount rate yields a stock price of about $200....
...He says Vanguard will never abandon its licensing contracts with Russell Indexes and S&P Dow Jones Indices because of their formidable brand recognition....
...“If Mr Abe cannot judge on this, he cannot judge on anything,” he said (Financial Times)....
International Edition